Female Fertility Preservation Using Ovarian Tissue Cryopreservation Before Highly Gonadotoxic Cancer Treatment
NCT ID: NCT03180827
Last Updated: 2022-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
100 participants
INTERVENTIONAL
2015-06-30
2100-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Due to the remarkable improvement in treatments these last decades, long term survival can be expected in more than 80% of childhood cancer patients. Unfortunately, cancer treatments can be harmful to the gonads and can affect reproductive and endocrine functions. While loss of fertility is a major concern for most patients, only the experimental option of ovarian tissue cryopreservation can be proposed to prepubertal girls with a high risk of infertility. For pubertal patient, cryopreservation of mature oocytes after ovarian stimulation can be offered if oncological treatment debut can be delayed. As it is often not possible, ovarian tissue cryopreservation can also be offered.
Primary aims
\- To cryopreserve ovarian tissue of pre or peripubertal patient who will be receiving highly gonadotoxic oncological treatment.
Secondary aims
* To create a database in order to record clinical and biological follow-up data
* To pool resources with Fertisave Registry
* To create a research biobank for future research projects
Multicentric study: HUG, CHUV
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ovarian Tissue Cryopreservation in Children
NCT02646384
Fertility Preservation by Ovarian and Oocyte Cryopreservation
NCT00578500
Cryopreservation of Ovarian Tissue
NCT01558544
Ovarian Tissue Cryopreservation for Fertility Preservation
NCT01682525
Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors
NCT02400827
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ovarian tissue cryopreservation
ovarian tissue biopsy
ovarian tissue biopsy during general anesthesia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ovarian tissue biopsy
ovarian tissue biopsy during general anesthesia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient presenting high risk of infertility because of gonadotoxic treatments (i.e. high dose of alkylating agents, ovarian irradiation, total body irradiation)
* Multidisciplinary team consensus in favour to proposition to cryopreserve ovarian tissue.
Exclusion Criteria
* Refusal of the patient and/or her parents
* Treatments that are not highly gonadotoxic
2 Months
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gumy-Pause Fabienne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gumy-Pause Fabienne
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fabienne Gumy-Pause, Dr
Role: STUDY_CHAIR
University Hospital, Geneva
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Geneva University Hospitals
Geneva, , Switzerland
CHUV
Lausanne, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Maja Beck Popovic, Prof
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PB_2017-00536 (15-073)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.